A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis.
about
What makes psoriatic and rheumatoid arthritis so different?Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasisThe Changing Face of Clinical Trials in Psoriatic Arthritis.Systemic methotrexate therapy for psoriasis: past, present and future.The importance of disease associations and concomitant therapy for the long-term management of psoriasis patientsA randomized placebo-controlled trial of methotrexate in psoriatic arthritisA Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2.Emerging drugs for psoriasis.P-glycoprotein and drug resistance in systemic autoimmune diseases.Combination systemic therapies in psoriatic arthritis.The use of methotrexate in dermatology: a review.Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.Psoriatic arthritis: current therapy and future directions.Ustekinumab for the treatment of psoriatic arthritis.Focus on the potential effects of treatments for spondylarthritides on cardiovascular risk.Advances in the management of psoriatic arthritis.Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.Pharmacological therapy of spondyloarthritis.Psoriatic arthritis: latest treatments and their place in therapy.Apremilast for the treatment of psoriatic arthritis.European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review.British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016.Update in treatment options for psoriatic arthritis.Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate.A retrospective analysis of combination methotrexate-cyclosporine therapy in moderate-severe psoriasis.Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis.[Psoriatic arthritis : Overview of drug therapy options and administration characteristics].Musculoskeletal ultrasonography for psoriatic arthritis and psoriasis patients: a systematic literature review.[Psoriatic arthritis : Overview of drug therapy options and administration characteristics].Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review.Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches.Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial.Cost–effectiveness of tumor necrosis factor-α antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitisPhase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate
P2860
Q26778261-384F9F4E-57EB-4D55-BB3C-97BCE9CB8E42Q27693878-FE20ED03-BE5A-42F4-B344-2DCC78099151Q30235002-02D40FC3-A365-410D-8349-6BEBA20591AAQ34356265-1A7DB9B6-E5F2-4B3C-A767-0FCA0736BDE9Q35230117-E07DE374-0FD3-427E-A0A1-56BAA5DF6C14Q36096798-2E9BEC8C-8057-494E-9217-785FDE2FAE6AQ36434813-7073DCC9-A1A5-4CEE-BCD3-05406348E779Q36634244-AC01457B-DD81-4CCE-AA61-F716589BDB0AQ37684129-BDEA58B7-D887-4DE6-B4D9-C25984844401Q37776265-33E53FA4-925B-4CDD-9010-123682DFBACDQ37981730-DE8B3BF3-8F54-48FA-AD1B-D6882926E7FEQ38098466-FD7EE597-D6DF-4249-BC13-62671DFA6519Q38118343-C978D10C-B9D8-446C-887D-0D499F6D10F4Q38177336-5F58AAE2-1490-4F8A-810C-A986064D9E3EQ38177340-B51A1AC3-7C84-4B4D-90AC-A7EF57D529E7Q38227264-6E0942A0-4E3C-4DCA-BBDC-F5F07E5BD823Q38416536-332CF1D4-7B9A-4ECF-BFF0-57EC5A3D4AE9Q38527552-32ED63F5-A3CC-4FCD-9DEF-C3EE0CD19B49Q38542095-707B8FF3-8AC5-42B6-A87A-FC7978A57B2CQ38616811-13F9F595-B4EF-4AAF-8BE7-D30EDEE8E6C8Q38661777-7362B1E3-9D4F-4F1F-90EF-1A3E8FDCCE78Q38690324-433A2FF3-2FF0-4628-AC5C-4C429DFAC8FDQ38925320-A552FC71-A1EB-466D-87BF-41244E50778BQ40590985-8DC1F423-F5BC-451F-A462-E063A2304279Q43061552-0D503393-AFC7-4BA4-AD29-1401420F388AQ43641073-4B16929B-8566-4B38-8AD4-49B930908B82Q44714485-1C670C82-0DF0-480E-BDE5-32493F5CAFC2Q46129663-1DA71EF9-DB66-4D67-B792-998838B4EA8AQ52927228-1FCE27CD-EC5C-4F83-B8C0-3B5FCAC99A14Q53284853-1F40BB1B-A16C-4515-8B09-1927F40D101FQ53760739-9B49F143-D17E-4734-95A2-E3BCD5D6EC5BQ55109332-27214CC2-A85F-415D-98CA-C521F6ADAD94Q55119199-2FAB764A-11C1-457C-9AC9-F83857CA9433Q55316418-EE3F757E-C40A-40EF-84C6-43EC1B543F13Q57658712-ED4BAD4C-DE4A-44D6-B329-D75368FE2FEAQ59137786-974D783E-5837-40E9-969A-0B8A6EABECC2
P2860
A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
A randomised, double blind, pl ...... th active psoriatic arthritis.
@ast
A randomised, double blind, pl ...... th active psoriatic arthritis.
@en
A randomised, double blind, pl ...... th active psoriatic arthritis.
@en-gb
type
label
A randomised, double blind, pl ...... th active psoriatic arthritis.
@ast
A randomised, double blind, pl ...... th active psoriatic arthritis.
@en
A randomised, double blind, pl ...... th active psoriatic arthritis.
@en-gb
prefLabel
A randomised, double blind, pl ...... th active psoriatic arthritis.
@ast
A randomised, double blind, pl ...... th active psoriatic arthritis.
@en
A randomised, double blind, pl ...... th active psoriatic arthritis.
@en-gb
P2093
P2860
P356
P1476
A randomised, double blind, pl ...... th active psoriatic arthritis.
@en
P2093
Dijkmans BA
Gerards AH
Steinfeld SD
Wakefield R
Westhovens R
van Kuijk AW
P2860
P304
P356
10.1136/ARD.2004.024463
P407
P50
P577
2004-11-04T00:00:00Z
P5875
P6179
1015658441